Search results for " Ly"

showing 10 items of 2487 documents

Minimal Lesions of the Small Intestinal Mucosa: More than Morphology

2020

Minimal lesions of the small bowel are mucosal changes characterized by an increased number of intraepithelial lymphocytes (with or without crypt hyperplasia) and normal villous architecture. Such changes are associated with a wide spectrum of conditions, ranging from food intolerances to infections, and from drugs to immune diseases, with different clinical profiles and manifestations, which complicates the formulation of a differential diagnosis. Patient history, symptom evaluation, and histopathology are the diagnostic features needed to establish a correct diagnosis. Physicians should assist pathologists in formulating a precise morphological evaluation by taking well-oriented small int…

medicine.medical_specialtyPathologySettore MED/09 - Medicina InternaPhysiologyBiopsyDiseaseWheat HypersensitivityMucosal enteropathiesNONon-celiac gluten/wheat sensitivityDiagnosis Differential03 medical and health sciencesIntra-epithelial lymphocytes0302 clinical medicineIntolerancesPredictive Value of TestsRisk FactorsInternal medicineIntestine SmallmedicineHumansCeliac diseaseMedical historyIntestinal MucosaIntraepithelial LymphocytesImmunoglobulin A-tranglutaminase 2 depositiHyperplasiaImmunoglobulin A-tranglutaminase 2 depositisbusiness.industryGastroenterologyPotential celiac diseaseMucosal enteropathieHepatologySmall intestineIntra-epithelial lymphocytemedicine.anatomical_structureCeliac disease Immunoglobulin A-tranglutaminase 2 depositis Intra-epithelial lymphocytes Mucosal enteropathies Non-celiac gluten/wheat sensitivity Potential celiac disease030220 oncology & carcinogenesisIntraepithelial lymphocyte030211 gastroenterology & hepatologyHistopathologyDifferential diagnosisbusiness
researchProduct

Primary extranodal non-Hodgkin lymphomas of the uterus and the breast: report of three cases

1995

The authors describe one case of a rare primitive non-Hodgkin lymphoma of the uterus, and two cases of primary non-Hodgkin lymphoma of the breast. Histologically, the uterine lymphoma, although clinically confined to the uterus, was a diffuse large cell lymphoma, group G according to the Working formulation for Clinical Usage. The two cases of breast lymphoma were a centrocytic-centroblastic and a lymphoplasmocytoid non-Hodgkin lymphoma, respectively. All cases were initally treated with radical surgery plus radiotherapy, but the first patient showed an early recurrence at distant sites, which required systemic cytotoxic chemotherapy. The patient with uterine non-Hodgkin lymphoma received a…

medicine.medical_specialtyPathologyWorking Formulationmedicine.medical_treatmentMammary glandUterusBreast NeoplasmsCHOPimmune system diseaseshemic and lymphatic diseasesAntineoplastic Combined Chemotherapy ProtocolsHumansMedicineRadical surgeryChemotherapybusiness.industryLymphoma Non-HodgkinGeneral MedicineMiddle Agedmedicine.diseaseCombined Modality TherapyLymphomaRadiation therapymedicine.anatomical_structureOncologyUterine NeoplasmsFemaleSurgeryLymphoma Large B-Cell DiffuseRadiologybusinessEuropean Journal of Surgical Oncology (EJSO)
researchProduct

Gene Rearrangements and Other Molecular Features in Aggressive B-Cell Lymphomas of Patients with and without HIV-Infection

2015

Abstract Aggressive B-cell Lymphomas are the second most frequent AIDS-defining cancers. Few studies have compared the molecular characteristics of aggressive B-cell lymphomas in patients with and without HIV-infection; and to our knowledge, there are no reports comparing the incidence of gene rearrangements between the two groups and their impact on outcome in series treated with RCHOP. We retrospectively studied two series of patients with (N=32) and without HIV-infection (N=43) with diffuse large B-cell lymphomas (DLBCL) NOS (75% and 70%, respectively), T-rich DLCBL (13% and 5%), transformed DLBCL (3% and 14%) and double-hit (DH) DLCBL (9% and 11%) [defined by translocations affecting MY…

medicine.medical_specialtyPathologybusiness.industryIncidence (epidemiology)ImmunologyFollicular lymphomaCell BiologyHematologyCHOPmedicine.diseaseBiochemistryGastroenterologyLymphomaExact testInternational Prognostic IndexInternal medicinemedicineProgression-free survivalbusinessDiffuse large B-cell lymphomaBlood
researchProduct

Verbesserte Orts- und Kontrastauflösung in der Ultraschalldiagnostik durch Nutzung Harmonischer Frequenzen

2001

Background: The aim of new techniques in head and neck sonography is to increase the sensitivity and the specificity of the examination, With tissue harmonic imaging (THI) and contrast harmonic imaging (CHI) new techniques are available which allow increased contrast and resolution in head and neck sonography as well as a better detection of small blood vessels. Methods: We studied whether these techniques improve sonographic detection of head and neck lymph nodes and primary tumours of the upper aerodigestive tract. Results: The results indicate that THI allows a better detection of cervical lymph nodes. Furthermore, intranodal structures and the borders of the lymph node can be better det…

medicine.medical_specialtyPathologybusiness.industrySecond-harmonic imaging microscopymedicine.anatomical_structureUpper aerodigestive tractOtorhinolaryngologyEpidermoid carcinomaCervical lymph nodesMedicineRadiologyLymphbusinessHead and neckLymph nodeTumour statusLaryngo-Rhino-Otologie
researchProduct

Factores de predicción de dosificación inadecuada de rivaroxabán utilizando la ecuación de CKD-EPI

2021

Yes

medicine.medical_specialtyPatientsCKD-EPI:Diseases::Hemic and Lymphatic Diseases::Hematologic Diseases::Blood Coagulation Disorders [Medical Subject Headings]Dosislcsh:RC870-923:Anatomy::Cardiovascular System::Blood Vessels::Arteries::Aorta [Medical Subject Headings]:Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings]DosageRivaroxabanRivaroxabánmedicineRenal insufficiency chronicInsuficiencia renal crónicaGynecology:Diseases::Male Urogenital Diseases::Urologic Diseases::Kidney Diseases::Renal Insufficiency::Renal Insufficiency Chronic [Medical Subject Headings]:Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Clinical Trials as Topic::Observational Study as Topic [Medical Subject Headings]business.industry:Analytical Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Drug Therapy::Drug Dosage Calculations [Medical Subject Headings]lcsh:Diseases of the genitourinary system. Urology:Persons::Persons::Patients [Medical Subject Headings]NephrologyPacientesDosificaciónbusiness:Analytical Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Drug Therapy::Drug Prescriptions [Medical Subject Headings]Nefrología
researchProduct

Risk factors for refractory Kawasaki disease: clinical records of the paediatric clinic of palermo

2014

Kawasaki disease (KD) is an acute, self-limited febrile illness that mainly affecting small- to medium-sized vessels and occurs in early childhood. The etiology is currently unknown, however it likely results from an immunologic response triggered by microbial agents, with documented genetic susceptibility. Intravenous administration of immunoglobulin (IVIG) is the gold standard therapy for coronary arteritis in the acute phase of KD; some patients do not respond to IVIG and coronary aneurysms continue to develop in 5%. The most serious complications are coronary vasculitis and aneurysms. 15% of these patients do not respond to IVIG (Refractory KD:RMK) and have a higher risk of aneurysms.

medicine.medical_specialtyPediatricsbiologybusiness.industryGold standardmedicine.diseaseRheumatologySettore MED/38 - Pediatria Generale E SpecialisticaRefractoryRheumatologyhemic and lymphatic diseasesInternal medicinePoster PresentationPediatrics Perinatology and Child HealthmedicineGenetic predispositionEtiologybiology.proteinImmunology and AllergyKawasaki diseaseKawasaki disease risk factorsPediatrics Perinatology and Child HealthAntibodyVasculitisbusinessPediatric Rheumatology
researchProduct

Luspatercept Response in ESA-NaïVe/RS+ Patients and RS- Patients with Low-Intermediate Risk Myelodysplastic Syndromes (MDS)

2016

Abstract Background: Management of anemia is a common therapeutic challenge in patients with myelodysplastic syndromes (MDS). Luspatercept (ACE-536), a fusion protein containing modified activin receptor type IIB, is being developed for treatment of anemia in lower-risk MDS. Luspatercept binds GDF11 and other TGF-β superfamily ligands to promote late-stage erythroid differentiation and increase hemoglobin (Hgb) levels (Suragani R, Nat Med, 2014 and Attie K, Am J Hematol, 2014). Aims: This is an ongoing, phase 2, multicenter, open-label study to evaluate the effects of luspatercept in patient (pts) with low-intermediate risk MDS. Endpoints included erythroid response (IWG HI-E), RBC transfus…

medicine.medical_specialtyPediatricsbusiness.industryAnemiaMyelodysplastic syndromesImmunologyPhases of clinical researchCell BiologyHematologymedicine.diseaseBiochemistryGastroenterologyhemic and lymphatic diseasesPharmacodynamicsInternal medicineLuspaterceptCohortmedicineIntermediate riskbusinessLenalidomidemedicine.drugBlood
researchProduct

Effect of Prognostic Risk Classification on Temsirolimus Efficacy and Safety Outcomes in Patients with Relapsed/Refractory Mantle Cell Lymphoma

2011

Abstract Abstract 2708 Background: The simplified Mantle Cell Lymphoma International Prognostic Index (MIPI) has been shown to be a good predictor of patient survival (Blood 2008;111:558–65; Blood 2010;115:1530–1533). This post hoc study analyzed data from a randomized, phase III clinical trial investigating temsirolimus (TEM) in relapsed/refractory mantle cell lymphoma (MCL) in which TEM 175/75 (175 mg for first 3 weeks then 75 mg weekly) demonstrated significantly longer progression-free survival (PFS) vs investigator's choice of therapy (INV; 4.8 vs 1.9 months, respectively; hazard ratio [HR]=0.44; P=.0009; J Clin Oncol 2009;27:3822–9). Patients receiving TEM 175/25 (175 mg for first 3 w…

medicine.medical_specialtyPerformance statusAnemiabusiness.industryIncidence (epidemiology)ImmunologyHazard ratioCell BiologyHematologymedicine.diseaseBiochemistryGastroenterologyTemsirolimusInternational Prognostic IndexRenal cell carcinomaInternal medicinemedicineMantle cell lymphomabusinessmedicine.drugBlood
researchProduct

Clinical conditions responsible for hyperviscosity and skin ulcers complications

2017

In this brief review, we have examined some clinical conditions that result to be associated to an altered hemorheological profile and at times accompanied by skin ulcers. This skin condition may be observed in patients with the following condtions, such as primary polycythemic hyperviscosity (polycythemia, thrombocytemia) treated with hydroxyurea, primary plasma hyperviscosity (multiple myeloma, cryoglobulinemia, cryofibrinogenemia, dysfibrinogenemia, and connective tissue diseases), primary sclerocythemic hyperviscosity (hereditary spherocytosis, thalassemia, and sickle cell disease). In addition, it may be present in patients with secondary hyperviscosity conditions such as diabetes mell…

medicine.medical_specialtyPhysiologyChronic venous insufficiencyBlood viscosityHyperviscosity syndromeCryofibrinogenemiaHyperviscosity030204 cardiovascular system & hematologyGastroenterologyHyperviscosity syndrome; blood viscosity; skin ulcers030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineskin ulcershemic and lymphatic diseasesPhysiology (medical)Internal medicineHyperviscosity syndromeSkin UlcermedicineHumansbusiness.industryHematologyCritical limb ischemiaSkin ulcermedicine.diseaseCryoglobulinemiablood viscositymedicine.symptomCardiology and Cardiovascular Medicinebusiness
researchProduct

Adipose Tissue: ILC2 Crank Up the Heat

2015

White-to-beige conversion of adipocytes is one of the most promising approaches to therapeutically target obesity; however, the signals driving this process had largely remained unclear. Recently, two publications, Brestoff et al. (2014) in Nature and Lee et al. (2015) in Cell, showed that group 2 innate lymphoid cells directly regulate adipocyte differentiation and drive the growth of beige fat.

medicine.medical_specialtyPhysiologyInnate lymphoid cellInnate immunologyAdipose tissueCell BiologyBiologychemistry.chemical_compoundEndocrinologychemistryAdipocyteInternal medicinemedicineMolecular BiologyCell Metabolism
researchProduct